Pharmacophore-based virtual screening: a review of recent applications

Bibliography

• Langer T, Krovat EM. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr Opin Drug Discov Devel 2003;6(3):370-6
   PubMed Web of Science ®Google Scholar
• Wolber G, Seidel T, Bendix F, Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov Today 2008;13(1-2):23-9
   PubMed Web of Science ®Google Scholar
• Wermuth CG. Pharmacophores: historical perspective and viewpoint from a medicinal chemist. In pharmacophores and pharmacophore searches. vol. 32; Wiley-VCH, 2006. p. 3-13
   Google Scholar
• Hou T, Wang J, Zhang W, Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem 2006;13(22):2653-67
   PubMed Web of Science ®Google Scholar
• Dror O, Shulman-Peleg A, Nussinov R, Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr Med Chem 2004;11(1):71-90
   PubMed Web of Science ®Google Scholar
• Catalyst, Accelrys. Available from: http://www.accelrys.com
   Google Scholar
• DISCO, Tripos, Inc. Available from: http://www.tripos.com
   Google Scholar
• GASP, Tripos, Inc. Available from: http://www.tripos.com
   Google Scholar
• Phase, Schrodinegr, Inc. Available from: http://www.schrodinger.com
   Google Scholar
• Molecular Operating Environment (MOE), Chemical Computing Group. Available from: http://www.chemcomp.com
   Google Scholar
• Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005;45:160-9
   PubMed Web of Science ®Google Scholar
• CONCORD, Tripos, Inc. Available from: http://www.tripos.com
   Google Scholar
• CORINA, Molecular-networks. Available from: http://www.molecular-networks.de
   Google Scholar
• Macromodel, Schrodinger. Available from: http://www.schrodinger.com
   Google Scholar
• Confort, Tripos, Inc. Available from: http://www.tripos.com
   Google Scholar
• Hou T, Xu X. Recent development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 2004;10(9):1011-33
   PubMed Web of Science ®Google Scholar
• Sun H. Pharmacophore-based virtual screening. Curr Med Chem 2008;15(10):1018-24
   PubMed Web of Science ®Google Scholar
• Köppen H. Virtual screening–what does it give us? Curr Opin Drug Discov Devel 2009;12(3):397-407
   PubMed Web of Science ®Google Scholar
• Güner OF. History and evolution of the pharmacophore concept in computer-aided drug design. Curr Top Med Chem 2002;2(12):1321-32
   PubMedGoogle Scholar
• Güner O, Clement O, Kurogi Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr Med Chem 2004;11(22):2991-3005
   PubMed Web of Science ®Google Scholar
• Khedkar SA, Malde AK, Coutinho EC, Pharmacophore modeling in drug discovery and development: an overview. Med Chem 2007;3(2):187-97
   PubMed Web of Science ®Google Scholar
• McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007;11(5):494-502
   PubMed Web of Science ®Google Scholar
• Lyne PD. Structure-based virtual screening: an overview. Drug Discov Today 2002;7(20):1047-55
   PubMed Web of Science ®Google Scholar
• Ravikumar M, Pavan S, Bairy S, Virtual screening of cathepsin k inhibitors using docking and pharmacophore models. Chem Biol Drug Des 2008;72(1):79-90
   PubMed Web of Science ®Google Scholar
• Li HF, Lu T, Zhu T, Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. Eur J Med Chem 2009;44(3):1240-9
   PubMed Web of Science ®Google Scholar
• Toba S, Srinivasan J, Maynard AJ, Using pharmacophore models to gain insight into structural binding and virtual screening: an application study with CDK2 and human DHFR. J Chem Inf Model 2006;46(2):728-35
   PubMed Web of Science ®Google Scholar
• Zou J, Xie HZ, Yang SY, Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. J Mol Graph Model 2008;27(4):430-8
   PubMed Web of Science ®Google Scholar
• Xie HZ, Li LL, Ren JX, Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg Med Chem Lett 2009;19(7):1944-9
   PubMed Web of Science ®Google Scholar
• Xie QQ, Xie HZ, Ren JX, Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. J Mol Graph Model 2009;27(6):751-8
   PubMed Web of Science ®Google Scholar
• Chen JJ, Liu TL, Yang LJ, Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chem Pharm Bull (Tokyo) 2009;57(7):704-9
   PubMed Web of Science ®Google Scholar
• Krovat EM, Frühwirth KH, Langer T. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J Chem Inf Model 2005;45(1):146-59
   PubMed Web of Science ®Google Scholar
• Zhu T, Jiao Y, Chen YD, Pharmacophore identification of Raf-1 kinase inhibitors. Bioorg Med Chem Lett 2008;18(7):2346-50
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253-65
   PubMed Web of Science ®Google Scholar
• Chiang YK, Kuo CC, Wu YS, Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem 2009;52(14):4221-33
   PubMed Web of Science ®Google Scholar
• Liou JP, Mahindroo N, Chang CW, Structure-activity relationship studies of 3-aroylindoles as potent antimitotic Agents. Chem Med Chem 2006;1(10):1106-18
   Google Scholar
• Kim do Y, Kim KH, Kim ND, Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem 2006;49(19):5664-70
   PubMed Web of Science ®Google Scholar
• Weisenberg RC, Borisy GG, Taylor EW. The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry 1968;7:4466-79
   PubMed Web of Science ®Google Scholar
• Edwards ML, Stemerick DM, Sunkara PS. Chalcones: a new class of antimitotic agents. J Med Chem 1990;33:1948-54
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4(12):927-36
   PubMed Web of Science ®Google Scholar
• Deng XQ, Wang HY, Zhao YL, Pharmacophore modeling and virtual screening for identification of new Aurora-A kinase inhibitors. Chem Biol Drug Des 2008;71:533-9
   PubMed Web of Science ®Google Scholar
• Boyer SJ. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr Top Med Chem 2002;2:972-1000
   Google Scholar
• Yu H, Wang Z, Zhang L, The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Chem Biol Drug Des 2007;69(3):204-11
   PubMed Web of Science ®Google Scholar
• Barnum D, Greene J, Smellie A, Identification of common functional configurations among molecules. J Chem Inf Comput Sci 1996;36:563-71
   PubMedGoogle Scholar
• Miyazaki Y, Matsunaga S, Tang J, Novel 4-amino-furo[2,3-d] pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett 2005;15(9):2203-7
   PubMed Web of Science ®Google Scholar
• Lyne PD, Kenny PW, Cosgrove DA, Identification of compounds with nanomolar binding affinity for heckpoint Kinase-1 using knowledge-based virtual screening. J Med Chem 2004;47:1962-8
   PubMed Web of Science ®Google Scholar
• Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408(6811):433-9
   PubMed Web of Science ®Google Scholar
• Hindle SA, Rarey M, Buning C, Flexible docking under pharmacophore type constraints. J Comput Aided Mol Des 2002;16(2):129-49
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Eng J Med 2003;348(24):2431-42
   PubMed Web of Science ®Google Scholar
• Neves MA, Dinis TC, Colombo G, An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem 2009;44(10):4121-7
   PubMed Web of Science ®Google Scholar
• Dayam R, Al-Mawsawi LQ, Zawahir Z, Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J Med Chem 2008;51(5):1136-44
   PubMed Web of Science ®Google Scholar
• Barreca ML, Rao A, De Luca L, Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Comput Sci 2004;44(4):1450-5
   PubMedGoogle Scholar
• De Luca L, Barreca ML, Ferro S, Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. Chem Med Chem 2009;4(8):1311-6
   Google Scholar
• Mustata GI, Brigo A, Briggs JM. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg Med Chem Lett 2004;14(6):1447-54
   PubMed Web of Science ®Google Scholar
• Pandit D, So SS, Sun H. Enhancing specificity and sensitivity of pharmacophore-based virtual screening by incorporating chemical and shape features-a case study of HIV protease inhibitors. J Chem Inf Model 2006;46(3):1236-44
   PubMed Web of Science ®Google Scholar
• Steindl TM, Schuster D, Laggner C, Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models. J Chem Inf Model 2007;47(2):563-71
   PubMed Web of Science ®Google Scholar
• Pérez-Nueno VI, Pettersson S, Ritchie DW, Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J Chem Inf Model 2009;49(4):810-23
   PubMed Web of Science ®Google Scholar
• Discovery Studio, Accelrys. Available from: http://www.accelrys.com
   Google Scholar
• Ryu K, Kim ND, Choi SI, Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg Med Chem 2009;17(8):2975-82
   PubMed Web of Science ®Google Scholar
• Melagraki G, Afantitis A, Sarimveis H, Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. Bioorg Med Chem 2007;15(23):7237-47
   PubMed Web of Science ®Google Scholar
• Corbeil CR, Englebienne P, Yannopoulos CG, Docking ligands into flexible and solvated macromolecules. 2. Development and application of fitted 1.5 to the virtual screening of potential HCV polymerase inhibitors. J Chem Inf Model 2008;48(4):902-9
   PubMed Web of Science ®Google Scholar
• Kim J, Kim KS, Kim DE, Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening. Chem Biol Drug Des 2008;72(6):585-91
   PubMed Web of Science ®Google Scholar
• Steindl T, Langer T. Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening. J Chem Inf Comput Sci 2004;44(5):1849-56
   PubMedGoogle Scholar
• Kim J, Lee C, Chong Y. Identification of potential influenza virus endonuclease inhibitors through virtual screening based on the 3D-QSAR model. SAR QSAR Environ Res 2009;20(1):103-18
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yap YL, Altmeyer RM. Generation of predictive pharmacophore model for SARS-coronavirus main proteinase. Eur J Med Chem 2005;40(1):57-62
   PubMed Web of Science ®Google Scholar
• Sirois S, Wei DQ, Du Q, Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J Chem Inf Comput Sci 2004;44(3):1111-22
   PubMedGoogle Scholar
• Tsai KC, Chen SY, Liang PH, Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 2006;49(12):3485-95
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Angeli A, Atkinson AB, Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88(12):, 5593-602
   Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Definition of metabolicsyndrome: Report of the National Heart, Lung, and Blood Institute/American HeartAssociation conference on scientific issues related to definition. Circulation 2004;109(3):433-8
   PubMed Web of Science ®Google Scholar
• Yang H, Dou W, Lou J, Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Bioorg Med Chem Lett 2008;18(4):1340-5
   PubMed Web of Science ®Google Scholar
• Yang H, Shen Y, Chen J, Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. Eur J Med Chem 2009;44(3):1167-71
   PubMed Web of Science ®Google Scholar
• Rafferty SP, Guillemette JG, Berghuis AM, Mechanistic and structural contributions of critical surface and internal residues to cytochrome c electron transfer reactivity. Biochemistry 1996;35(33):10784-92
   PubMed Web of Science ®Google Scholar
• GLIDE, Schrodinger. Available from: http://www.schrodinger.com
   Google Scholar
• Schuster D, Maurer EM, Laggner C, The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem 2006;49(12):3454-66
   PubMed Web of Science ®Google Scholar
• Wang H, Duffy RA, Boykow GC, Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. J Med Chem 2008;51(8):2439-46
   PubMed Web of Science ®Google Scholar
• Foloppe N, Benwell K, Brooks TD, Discovery and functional evaluation of diverse novel human CB(1) receptor ligands. Bioorg Med Chem Lett 2009;19(15):4183-90
   PubMed Web of Science ®Google Scholar
• Ward RA, Perkins TD, Stafford J. Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. J Med Chem 2005;48(22):6991-6
   PubMed Web of Science ®Google Scholar
• Lyne PD, Kenny PW, Cosgrove DA, Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J Med Chem 2004;47(8):1962-8
   PubMed Web of Science ®Google Scholar
• OMEGA, Openeye Science. Available from: http://www.openeyes.com
   Google Scholar
• Stockel-Maschek A, Mrestani-Klaus C, Stiebitz B, Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim Biophys Acta 2000;1479(1-2):15-31
   PubMed Web of Science ®Google Scholar
• Xu HE, Lambert MH, Montana VG, Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397-403
   PubMed Web of Science ®Google Scholar
• Markt P, Petersen RK, Flindt EN, Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. J Med Chem 2008;51(20):6303-17
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, The protein data bank. Nucleic Acids Res 2000;28:35-242
   Google Scholar
• Clement OO, Mehl AT. HipHop: pharmacophores based on multiple common-feature alignments. In: Pharmacophore perception, development, and use in drug design. International University Line, La Jolla, CA, 2000. p. 71-84
   Google Scholar
• Pipeline Pilot, Scitegic. Available from: http://www.scitegic.com
   Google Scholar
• ROCS, Openeye Scientific Software, Inc. Available from: http://www.openeyes.com
   Google Scholar
• EON, Openeye Scientific Software, Inc. Available from: http://www.openeyes.com
   Google Scholar
• Itoh Y, Kawamata Y, Harada M, Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422(6928):173-6
   PubMed Web of Science ®Google Scholar
• Tikhonova IG, Sum CS, Neumann S, Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 2008;51(3):625-33
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45(1):177-82
   PubMed Web of Science ®Google Scholar
• Larbig G, Pickhardt M, Lloyd DG, Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res 2007;4(3):315-23
   PubMed Web of Science ®Google Scholar
• Pickhardt M, von Bergen M, Gazova Z, Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2005;2(2):219-26
   PubMedGoogle Scholar
• Dror O, Schneidman-Duhovny D, Inbar Y, Novel approach for efficient pharmacophore-based virtual screening: method and applications. J Chem Inf Model 2009;49(10):2333-43
   PubMed Web of Science ®Google Scholar
• Schneidman-Duhovny D, Dror O, Inbar Y, Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules. J Comput Biol 2008;15(7):737-54
   PubMed Web of Science ®Google Scholar